Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDental/Oral & MaxillofacialRocky Mountain Saliva Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy DCP037.11

    Collection, Preparation, and Analysis of Saliva Sample for Laboratory or Point-of-Care Diagnostic Testing

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy DCP037.11 alerts

    Get alerted when Policy DCP037.11 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses saliva sample collection, preparation, laboratory or point-of-care analysis, and salivary flow measurement for oral disease risk assessment, oral cancer biomarkers, xerostomia, and hyposalivation.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCollection, Preparation, and Analysis of Saliva Sample for Laboratory or Point-of-Care Diagnostic Testing
    Policy CodePolicy DCP037.11
    Change TypeSupporting-information update
    Effective DateNov 1, 2026
    Next Review DateNot specified
    Key ActionRecognize that salivary diagnostic testing for periodontal disease, dental caries, or head and neck cancer lacks identified FDA-approved tests and requires further clinical validation before routine use.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Dental procedure codes listed
    0FDA-cleared salivary diagnostic tests identified
    28Oral-cancer biomarker articles reviewed
    18

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Oral-dryness diagnostic studies reviewed

    Potential Indications

    Potential indications for saliva sample collection, preparation, and laboratory analysis

    May be indicated for any of the following purposes:

    Potential indications

    • Oral disease risk assessment: Collection, preparation, and analysis of a saliva sample for laboratory diagnostic testing as part of oral disease risk assessment and subsequent management.
    • Oral cancer biomarker identification: Collection, preparation, and analysis of a saliva sample for identification of biomarkers associated with oral cancers.

    Potential indications for salivary flow measurement

    May be indicated for any of the following purposes:

    Potential indications

    • Systemic disease: Presence of systemic disease known to cause xerostomia, including Sjögren's syndrome, diabetes, or autoimmune disorders.
    • Polypharmacy.
    • Head and neck radiation therapy: Radiation therapy to the head and neck.
    • Sialagogue monitoring: Monitoring the effectiveness of sialagogues.

    Salivary Testing Codes

    Salivary Testingmixed
    D0417Collection and preparation of saliva sample for laboratory analysis.
    D0418Analysis of saliva sample-laboratory
    Salivary Testingmixed
    D0419Assessment of salivary flow by measurement.
    D0426Collection, preparation, and analysis of saliva sample - point-of-care

    Provider Considerations

    Denial Risk

    Insufficient Validation of Salivary Diagnostics

    Do not rely on salivary diagnostic testing as an established diagnostic method for periodontal disease, dental caries, or head and neck cancer. Large-scale, multicenter clinical trials and independent validation studies are still needed to establish clinical utility, including disease-specific markers, test sensitivity and specificity, and standardized sample collection and storage.

    • No FDA-approved salivary diagnostic tests are currently identified for evaluating risk of periodontal disease, dental caries, or head and neck cancer.
    • Treat salivary and oral-fluid diagnostics as insufficiently validated for these indications pending evidence of clinical utility and regulatory approval.

    Clinical Background

    Saliva is composed of water, mucus, proteins, minerals, and the enzyme amylase. It lubricates the mouth, protects teeth from bacterial acids, helps rebuild damaged enamel, and begins the initial stage of digestion.

    Salivary testing can provide additional information about bacteria, biomarkers, and saliva quality or quantity. Measuring salivary flow is an established method for assessing impaired salivary gland function, including in individuals with medical conditions or medication use associated with hyposalivation or xerostomia. Although salivary biomarkers may be relevant to evaluation of oral disease risk and oral cancer, clinical utility remains limited by the need for further validation and standardization; no FDA-approved salivary diagnostic tests are currently identified for evaluating periodontal disease, dental caries, or head and neck cancer.

    Key Definitions

    Risk Assessment
    DefinitionAnalysis of risks involved prior to action being taken.
    Sialagogue
    DefinitionA drug that promotes the secretion of saliva.
    Xerostomia
    DefinitionA subjective feeling of a dry mouth.
    Hyposalivation
    Definition
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCollection, Preparation, and Analysis of Saliva Sample for Laboratory or Point-of-Care Diagnostic Testing
    Policy CodePolicy DCP037.11
    Change TypeSupporting-information update
    Effective DateNov 1, 2026
    Next Review DateNot specified
    Key ActionRecognize that salivary diagnostic testing for periodontal disease, dental caries, or head and neck cancer lacks identified FDA-approved tests and requires further clinical validation before routine use.
    SourceLink
    On This Page
    Potential IndicationsSalivary Testing CodesProvider ConsiderationsClinical BackgroundKey Definitions
    The objective measure of decreased salivary gland function.